The Journal of Medical Sciences

Register      Login

VOLUME 5 , ISSUE 2 ( April-June, 2019 ) > List of Articles

Original Article

Impact of Levothyroxine Therapy on Lipid Profile Value in Patients of Subclinical Hypothyroidism

Deepesh K Maurya, Swapnav Borthakur, Nitin Nyaharkar

Keywords : Lipid profile, Subclinical hypothyroidism,Levothyroxine

Citation Information : Maurya DK, Borthakur S, Nyaharkar N. Impact of Levothyroxine Therapy on Lipid Profile Value in Patients of Subclinical Hypothyroidism. J Med Sci 2019; 5 (2):39-42.

DOI: 10.5005/jp-journals-10045-00119

License: CC BY-NC 4.0

Published Online: 00-06-2019

Copyright Statement:  Copyright © 2019; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Aim: The aim of this study is to study the effect of levothyroxine treatment on lipid profile in patients of subclinical hypothyroidism. Materials and methods: A randomized control trial, prospective study conducted on 22 cases of subclinical hypothyroidism with 22 control at the Downtown Hospital, Guwahati. Inclusion and exclusion criteria were undertaken. Levothyroxine therapy was given and was followed up after 3 months with thyroid and lipid profiles. Pretreatment and posttreatment values were compared using the paired t test using the statistical software SPPS v.19. Results: A statistical significance between pretreatment and posttreatment values is found to be in values of thyroid-stimulating hormone (TSH), cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglyceride (p < 0.05). There was no significant difference in the pretreatment and posttreatment T3 and T4 values. There was a mild increase in the value of HDL, a significant decrease in the value of TSH, cholesterol, very low-density lipoprotein (VLDL), and triglyceride. Conclusion: Lipid profiles are altered in patients with subclinical hypothyroidism compared to controls. Levothyroxine therapy has beneficial effect on lipid profile in patients with subclinical hypothyroidism.


PDF Share
  1. Albon LM, Franklyn JA. The thyroid: non-malignant disease. Michael G. Scott-Brown's Otolaryngology, Head and Neck Surgery, 7th ed., Great Britain: Edward Arnold Publishers Ltd; 2008. p. 357.
  2. Surks MI, Ortiz E, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004;291(2): 228–238. DOI: 10.1001/jama.291.2.228.
  3. Gharib H, Tuttle RM, et al. Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. Thyroid 2005;15(1):24–28. DOI: 10.1089/thy.2005.15.24.
  4. Chu JW, Crapo LM. The treatment of subclinical hypothyroidism is seldom necessary. J Clin Endocrinol Metab 2001;86(10):4591–4599. DOI: 10.1210/jcem.86.10.7961.
  5. Ness GC, Chambers CM. Feedback and hormonal regulation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase: the concept of cholesterol buffering capacity. Proc Soc Exp Biol Med 2000;224:8–19. DOI: 10.1046/j.1525-1373.2000.22359.x.
  6. Ito M, Takamatsu J, et al. Disturbed metabolism of remnant lipoproteins in patients with subclinical hypothyroidism. Am J Med 2004;117:696–699. DOI: 10.1016/j.amjmed.2004.04.027.
  7. Tian L, Song Y, et al. A novel role for thyroid-stimulating hormone: up-regulation of hepatic 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase expression through the cyclic adenosine monophosphate/protein kinase A/cyclic adenosine monophosphate-responsive element binding protein pathway. Hepatology 2010;52:1401–1409. DOI: 10.1002/hep.23800.
  8. Hashimoto K, Cohen RN, et al. Cross-talk between thyroid hormone receptor and liver X receptor regulatory pathways is revealed in a thyroid hormone resistance mouse model. J Biol Chem 2006;281: 295–302. DOI: 10.1074/jbc.M507877200.
  9. Canaris GJ, Manowitz NR, et al. The Colorado thyroid disease prevalence study. Arch Intern Med 2000;160(4):526–534. DOI: 10.1001/archinte.160.4.526.
  10. Bell GM, Todd WTA, et al. End-organ responses to thyroxine therapy in subclinical hypothyroidism. Clinical Endocrinology 1985;22:83–89. DOI: 10.1111/j.1365-2265.1985.tb01068.x.
  11. Ridgway EC, Cooper DS, et al. Peripheral responses to thyroid hormone before and after Lthyroxine therapy in patients with subclinical hypothyroidism. J Clin Endocrinol Metab 1981;53: 1238–1242. DOI: 10.1210/jcem-53-6-1238.
  12. Elder J, McLelland A, et al. The relationship between serum cholesterol and serum thyrotropin, thyroxine and tri-iodothyronine concentrations in suspected hypothyroidism. Ann Clin Biochem 1990;27:110–113. DOI: 10.1177/000456329002700204.
  13. Bandyopadhyay SK. Study of dyslipidemia in subclinical hypothyroidism. J Indian Med Assoc 2006;104:622–626.
  14. Asranna A, Taneja RS, et al. Dyslipidemia in subclinical hypothyroidism and the effect of thyroxine on lipid profile. Indian J Endocrinol Metab 2012;16(Suppl 2):S347–S349.
  15. Bakker SJL, Ter Maaten JC, et al. The relationship between Thyrotropin and Low Density Lipoprotein Cholesterol is modified by insulin sensitivity in healthy euthyroid subjects. J Clin Endocrinol Metab 2001;86:1206–1211.
  16. Meier C, Staub JJ, et al. TSH controlled L-Thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study). J Clin Endocrinol Metab 2001;86:4860–4866. DOI: 10.1210/jcem.86.10.7973.
  17. Atthans BU, Staub JJ, et al. LDL/HDL changes in subclinical hypothyroidism: possible risk factor for coronary heart disease. Clin Endocrinol 1988;28:157–163.
  18. Monzani F, Caraccio N, et al. Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 2004;89:2099–2106. DOI: 10.1210/jc.2003- 031669.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.